Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this research study is to determine whether a short-term administration of an investigational study drug may provide evidence of improvement in cognitive functioning in a group of stable male subjects with schizophrenia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pittsburgh
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: gamma-Aminobutyric Acid

Criteria

Inclusion Criteria:

• Male participants

• Between the ages of 18 and 50

• Meet diagnostic criteria for schizophrenia or schizoaffective disorder

• Are clinically stable for a minimum of 3 months on current dose of medication

• Are unemployed (i.e., work less than 20 hours per week at competitive employment)

Exclusion Criteria:

• Psychoactive substance dependence within the past 6 months or substance abuse within the past month

• History of head trauma or other neurological disorder

• Medical illness or medications, such as benzodiazepine treatment or HIV medications, that may be affected by study participation (the study doctor will discuss this with potential subjects)

• Mental retardation

• Seizure disorder

• History of a heart attack, arrhythmia, or other heart disease